XtalPi Expects to Swing to H1 Loss

MT Newswires Live07-27

XtalPi (HKG:2228) expects to report a net loss attributable to shareholders of 215 million yuan to 275 million yuan for the first half of 2026, compared with a net profit of 82.8 million yuan a year earlier.

The company expects revenue of 380 million yuan to 400 million yuan, down from 517.1 million yuan a year earlier, primarily due to the absence of a $51 million upfront payment from a major pipeline licensing project recognized in the prior-year period, according to a Hong Kong bourse filing.

The pharma research firm also cited a more than 50% increase in research and development spending driven by continued investment in autonomous laboratories, agentic systems and drug development programs.

The company is expected to report interim results by the end of August.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment